Cormorant Global Healthcare Master Fund, LP
CIK 0001618442 Name as filed on the most recent filing
Filed as Cormorant Global Healthcare Master Fund, LP (59)
153 transaction lines · from 59 filings · filed 2016-11-07 to 2026-08-10 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER BlossomHill Therapeutics, Inc. 1 filings
- ISSUER Bright Minds Biosciences Inc. 2 filings
- ISSUER Corbus Pharmaceuticals Holdings, Inc. 5 filings
- ISSUER EyePoint, Inc. 6 filings
- ISSUER MoonLake Immunotherapeutics 3 filings
- ISSUER OnKure Therapeutics, Inc. 2 filings
- ISSUER Immuneering Corp 3 filings
- ISSUER Ambrx Biopharma, Inc. 1 filings
- ISSUER Ambrx Biopharma Inc. 4 filings
- ISSUER GreenLight Biosciences Holdings, PBC 1 filings
- ISSUER Biomea Fusion, Inc. 2 filings
- ISSUER Erasca, Inc. 3 filings
- ISSUER Ventyx Biosciences, Inc. 1 filings
- ISSUER Pyxis Oncology, Inc. 1 filings
- ISSUER Tyra Biosciences, Inc. 1 filings
- ISSUER Aerovate Therapeutics, Inc. 1 filings
- ISSUER Elevation Oncology, Inc. 1 filings
- ISSUER Monte Rosa Therapeutics, Inc. 1 filings
- ISSUER Verve Therapeutics, Inc. 1 filings
- ISSUER Rain Therapeutics Inc. 1 filings
- ISSUER Design Therapeutics, Inc. 1 filings
- ISSUER Prometheus Biosciences, Inc. 1 filings
- ISSUER BioAtla, Inc. 1 filings
- ISSUER Olema Pharmaceuticals, Inc. 1 filings
- ISSUER Akouos, Inc. 1 filings
- ISSUER Avidity Biosciences, Inc. 1 filings
- ISSUER Axonics Modulation Technologies, Inc. 1 filings
- ISSUER Kezar Life Sciences, Inc. 1 filings
- ISSUER Kiniksa Pharmaceuticals, Ltd. 1 filings
- ISSUER Proteostasis Therapeutics, Inc. 8 filings
- ISSUER Apellis Pharmaceuticals, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-10 |
BlossomHill Therapeutics, Inc. BLSM |
P, Open-market purchase | 312,500 acquired | 16.00 | 5,000,000.00 | Form 4, filing 0001231919-26-000852 | |
| 2026-04-28 |
Bright Minds Biosciences Inc. DRUG |
S, Open-market sale | 109,331 disposed | 89.50 | 9,785,124.50 | Form 4, filing 0000929638-26-001708 | |
| 2025-12-11 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
S, Open-market sale | 30,029 disposed | 11.46 | 344,012.22 | Form 4, filing 0000929638-25-004597 | |
| 2025-12-04 |
EyePoint, Inc. EYPT |
S, Open-market sale | 60,000 disposed | 15.70 | 942,240.00 | Form 4, filing 0000929638-25-004521 | |
| 2025-09-30 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 5,827 disposed | 6.96 | 40,555.92 | Form 4, filing 0000929638-25-003712 | |
| 2025-09-29 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 3,390,943 disposed | 7.58 | 25,703,347.94 | Form 4, filing 0000929638-25-003712 | |
| 2025-09-29 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 2,800,000 disposed | 6.61 | 18,508,000.00 | Form 4, filing 0000929638-25-003712 | |
| 2025-09-29 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 232,460 disposed | 8.40 | 1,952,664.00 | Form 4, filing 0000929638-25-003712 | |
| 2025-09-29 |
MoonLake Immunotherapeutics MLTX |
S, Open-market sale | 70,748 disposed | 9.38 | 663,616.24 | Form 4, filing 0000929638-25-003712 | |
| 2025-05-15 |
OnKure Therapeutics, Inc. OKUR |
S, Open-market sale | 1,813,439 disposed | 1.85 | 3,363,022.63 | Form 4, filing 0000929638-25-001950 | |
| 2025-05-12 |
OnKure Therapeutics, Inc. OKUR |
S, Open-market sale | 24,300 disposed | 1.98 | 48,235.50 | Form 4, filing 0000929638-25-001870 | |
| 2024-10-16 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 39,743 acquired | 23.22 | 922,633.74 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-16 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 7,150 acquired | 24.03 | 171,814.50 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-16 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 3,107 acquired | 25.22 | 78,364.75 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-15 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 238,097 acquired | 4.53 | 1,078,674.65 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-15 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 63,173 acquired | 5.92 | 374,236.85 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-15 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 33,343 acquired | 6.42 | 214,218.77 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-15 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 19,169 acquired | 11.72 | 224,601.26 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-15 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 8,900 acquired | 7.31 | 65,016.28 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-15 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 4,609 acquired | 12.35 | 56,927.14 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-15 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 2,700 acquired | 9.26 | 25,008.48 | Form 4, filing 0000929638-24-003542 | |
| 2024-10-15 |
Bright Minds Biosciences Inc. DRUG |
P, Open-market purchase | 2,600 acquired | 8.80 | 22,890.40 | Form 4, filing 0000929638-24-003542 | |
| 2024-09-20 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 139,551 acquired | 20.42 | 2,849,352.32 | Form 4, filing 0000929638-24-003217 | |
| 2024-09-20 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 66,088 acquired | 19.61 | 1,296,051.77 | Form 4, filing 0000929638-24-003217 | |
| 2024-09-20 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 47,564 acquired | 21.47 | 1,021,389.34 | Form 4, filing 0000929638-24-003217 | |
| 2024-09-20 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 45,085 acquired | 17.48 | 787,860.38 | Form 4, filing 0000929638-24-003217 | |
| 2024-09-20 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 25,943 acquired | 18.36 | 476,313.48 | Form 4, filing 0000929638-24-003217 | |
| 2024-09-20 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 25,769 acquired | 22.23 | 572,793.33 | Form 4, filing 0000929638-24-003217 | |
| 2024-05-06 |
EyePoint Pharmaceuticals, Inc. EYPT |
P, Open-market purchase | 642,847 acquired | 11.70 | 7,521,309.90 | Form 4, filing 0000929638-24-001743 | |
| 2024-05-06 |
EyePoint Pharmaceuticals, Inc. EYPT |
P, Open-market purchase | 207,153 acquired | 12.36 | 2,560,411.08 | Form 4, filing 0000929638-24-001743 | |
| 2024-04-18 |
EyePoint Pharmaceuticals, Inc. EYPT |
P, Open-market purchase | 395,244 acquired | 17.62 | 6,964,199.28 | Form 4, filing 0000929638-24-001536 | |
| 2024-04-18 |
EyePoint Pharmaceuticals, Inc. EYPT |
P, Open-market purchase | 186,521 acquired | 18.90 | 3,525,246.90 | Form 4, filing 0000929638-24-001536 | |
| 2024-04-01 |
Immuneering Corp IMRX |
S, Open-market sale | 398,600 disposed | 2.90 | 1,155,940.00 | Form 4, filing 0000929638-24-001336 | |
| 2024-04-01 |
Immuneering Corp IMRX |
S, Open-market sale | 600 disposed | 3.03 | 1,818.00 | Form 4, filing 0000929638-24-001336 | |
| 2024-04-01 |
Immuneering Corp IMRX |
S, Open-market sale | 300 disposed | 3.06 | 919.50 | Form 4, filing 0000929638-24-001336 | |
| 2024-04-01 |
Immuneering Corp IMRX |
S, Open-market sale | 280 disposed | 2.97 | 831.60 | Form 4, filing 0000929638-24-001336 | |
| 2024-04-01 |
Immuneering Corp IMRX |
S, Open-market sale | 100 disposed | 3.07 | 307.00 | Form 4, filing 0000929638-24-001336 | |
| 2024-04-01 |
Immuneering Corp IMRX |
S, Open-market sale | 100 disposed | 3.05 | 305.00 | Form 4, filing 0000929638-24-001336 | |
| 2024-04-01 |
Immuneering Corp IMRX |
S, Open-market sale | 10 disposed | 3.01 | 30.10 | Form 4, filing 0000929638-24-001336 | |
| 2024-04-01 |
Immuneering Corp IMRX |
S, Open-market sale | 10 disposed | 2.98 | 29.80 | Form 4, filing 0000929638-24-001336 | |
| 2024-03-15 |
Immuneering Corp IMRX |
S, Open-market sale | 400,000 disposed | 2.14 | 856,400.00 | Form 4, filing 0000929638-24-001046 | |
| 2024-03-14 |
Immuneering Corp IMRX |
S, Open-market sale | 345,266 disposed | 3.24 | 1,116,935.51 | Form 4, filing 0000929638-24-001046 | |
| 2024-03-14 |
Immuneering Corp IMRX |
S, Open-market sale | 98,570 disposed | 4.24 | 418,429.65 | Form 4, filing 0000929638-24-001046 | |
| 2024-03-14 |
Immuneering Corp IMRX |
S, Open-market sale | 54,215 disposed | 5.37 | 291,351.41 | Form 4, filing 0000929638-24-001046 | |
| 2024-03-14 |
Immuneering Corp IMRX |
S, Open-market sale | 11,040 disposed | 5.97 | 65,886.72 | Form 4, filing 0000929638-24-001046 | |
| 2024-03-08 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 156,597 acquired | 45.26 | 7,087,580.22 | Form 4, filing 0000929638-24-000985 | |
| 2024-03-08 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 61,668 acquired | 44.62 | 2,751,626.16 | Form 4, filing 0000929638-24-000985 | |
| 2024-03-08 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 29,342 acquired | 41.23 | 1,209,770.66 | Form 4, filing 0000929638-24-000985 | |
| 2024-03-08 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 24,983 acquired | 42.25 | 1,055,531.75 | Form 4, filing 0000929638-24-000985 | |
| 2024-03-08 |
Corbus Pharmaceuticals Holdings, Inc. CRBP |
P, Open-market purchase | 18,548 acquired | 43.26 | 802,386.48 | Form 4, filing 0000929638-24-000985 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Cormorant Global Healthcare Master Fund, LP, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001618442
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6